This alert, designated as No. 043/2024, was published on the NAFDAC website and indicates that the counterfeit products were manufactured in February and June 2023. The expiration dates for these products are noted as May 2026 and June 2026, with Batch No: 7225119 and NAFDAC Registration No: A11-0299.
The agency identified Strides Arcolab Limited, located at 36/7, Suragajakkanahalli, Indlavadi Cross, Anekal Taluk, Bangalore- 562 106, India, as the manufacturer.
In the alert, NAFDAC instructed all zonal directors and 0800-162-3322 coordinators to conduct surveillance and remove counterfeit items from circulation in their respective areas. It urged importers, distributors, retailers, healthcare professionals, and caregivers to remain vigilant and refrain from importing, distributing, selling, or using these counterfeit products.
NAFDAC emphasized that all medical products should be sourced from authorized and licensed suppliers, and that the authenticity and condition of these products must be thoroughly verified.
The alert also encouraged healthcare professionals and consumers to report any suspicions regarding the sale of substandard or falsified medicines or medical devices to the nearest NAFDAC office. Nigerians are advised to contact NAFDAC at 0800-162-3322 or report suspicious activities via email at sf.alert@nafdac.gov.ng.
Furthermore, healthcare professionals and patients are encouraged to report any adverse effects or side effects associated with medicinal products or devices to the nearest NAFDAC office or through the E-reporting platforms available on the NAFDAC website, www.nafdac.gov.ng.
NAFDAC also recommended that Nigerians report any adverse effects using the Med-safety application, which can be downloaded from Android and iOS stores, or via email at pharmacovigilance@nafdac.gov.ng.
Healthcare professionals and patients are urged to report any adverse effects or side effects associated with medicinal products or devices to the nearest NAFDAC office or through the E-reporting platforms accessible on the NAFDAC website, www.nafdac.gov.ng.
Nigerians are also encouraged to report any adverse effects using the Med-safety application, which can be downloaded from both Android and iOS stores, or by emailing pharmacovigilance@nafdac.gov.ng.
NAFDAC has committed to uploading this information to the WHO Global Surveillance and Monitoring System (GSMS).